Published in Virus Weekly, November 25th, 1996
A single-dose rising study and a two-week, multiple-dose escalation study, involving 27 HIV positive patients, have been completed. Results indicate that Zintevir, administered at doses up to 6 mg/kg, is extremely well-tolerated. No clinically significant adverse events were reported.
Results also indicate that Zintevir plasma...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.